These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25213859)

  • 1. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice.
    Soufi N; Hall AM; Chen Z; Yoshino J; Collier SL; Mathews JC; Brunt EM; Albert CJ; Graham MJ; Ford DA; Finck BN
    J Biol Chem; 2014 Oct; 289(43):30177-88. PubMed ID: 25213859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple antisense oligonucleotides targeted against monoacylglycerol acyltransferase 1 (Mogat1) improve glucose metabolism independently of Mogat1.
    Lutkewitte AJ; Singer JM; Shew TM; Martino MR; Hall AM; He M; Finck BN
    Mol Metab; 2021 Jul; 49():101204. PubMed ID: 33676028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice.
    Hall AM; Soufi N; Chambers KT; Chen Z; Schweitzer GG; McCommis KS; Erion DM; Graham MJ; Su X; Finck BN
    Diabetes; 2014 Jul; 63(7):2284-96. PubMed ID: 24595352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis.
    Okuma C; Ohta T; Tadaki H; Ishigure T; Sakata S; Taniuchi H; Sano R; Hamada H; Kume S; Nishiu J; Kakutani M
    J Pharmacol Sci; 2015 Jul; 128(3):150-7. PubMed ID: 26215699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic monoacylglycerol acyltransferase 1 is induced by prolonged food deprivation to modulate the hepatic fasting response.
    Lutkewitte AJ; McCommis KS; Schweitzer GG; Chambers KT; Graham MJ; Wang L; Patti GJ; Hall AM; Finck BN
    J Lipid Res; 2019 Mar; 60(3):528-538. PubMed ID: 30610082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance.
    Popov VB; Jornayvaz FR; Akgul EO; Kanda S; Jurczak MJ; Zhang D; Abudukadier A; Majumdar SK; Guigni B; Petersen KF; Manchem VP; Bhanot S; Shulman GI; Samuel VT
    FASEB J; 2016 Mar; 30(3):1207-17. PubMed ID: 26644352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoacylglycerol Acyltransferase 1 Knockdown Exacerbates Hepatic Ischemia/Reperfusion Injury in Mice With Hepatic Steatosis.
    Liss KHH; Ek SE; Lutkewitte AJ; Pietka TA; He M; Skaria P; Tycksen E; Ferguson D; Blanc V; Graham MJ; Hall AM; McGill MR; McCommis KS; Finck BN
    Liver Transpl; 2021 Jan; 27(1):116-133. PubMed ID: 32916011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
    Choi CS; Savage DB; Kulkarni A; Yu XX; Liu ZX; Morino K; Kim S; Distefano A; Samuel VT; Neschen S; Zhang D; Wang A; Zhang XM; Kahn M; Cline GW; Pandey SK; Geisler JG; Bhanot S; Monia BP; Shulman GI
    J Biol Chem; 2007 Aug; 282(31):22678-88. PubMed ID: 17526931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.
    Yu XX; Watts LM; Manchem VP; Chakravarty K; Monia BP; McCaleb ML; Bhanot S
    PLoS One; 2013; 8(7):e66923. PubMed ID: 23922646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice.
    Carr RM; Patel RT; Rao V; Dhir R; Graham MJ; Crooke RM; Ahima RS
    Am J Physiol Regul Integr Comp Physiol; 2012 Apr; 302(8):R996-1003. PubMed ID: 22378776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver.
    Hall AM; Kou K; Chen Z; Pietka TA; Kumar M; Korenblat KM; Lee K; Ahn K; Fabbrini E; Klein S; Goodwin B; Finck BN
    J Lipid Res; 2012 May; 53(5):990-999. PubMed ID: 22394502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance.
    Brown JM; Betters JL; Lord C; Ma Y; Han X; Yang K; Alger HM; Melchior J; Sawyer J; Shah R; Wilson MD; Liu X; Graham MJ; Lee R; Crooke R; Shulman GI; Xue B; Shi H; Yu L
    J Lipid Res; 2010 Nov; 51(11):3306-15. PubMed ID: 20802159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice.
    Karavia EA; Papachristou DJ; Liopeta K; Triantaphyllidou IE; Dimitrakopoulos O; Kypreos KE
    Mol Med; 2012 Sep; 18(1):901-12. PubMed ID: 22576368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2-/-) or obese (ob/ob) mice.
    Agarwal AK; Tunison K; Dalal JS; Yen CL; Farese RV; Horton JD; Garg A
    J Lipid Res; 2016 Apr; 57(4):616-30. PubMed ID: 26880786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF; Purushotham A; Wendel AA; Belury MA
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
    Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.